Navigation Links
Study: Pulmatrix's PUR1900 Inhaled Cystic Fibrosis Drug Demonstrates High Lung Retention and Potency Against Fungal Infection
Date:10/8/2015

LEXINGTON, Mass., Oct. 8, 2015 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) today announced preclinical data showing that PUR1900 (iSPERSE™-formulated itraconazole), which is being developed as the first inhaled antifungal medication for cystic fibrosis, was active and potent in vitro against Aspergillus fumigatus, a pathogen causing pulmonary infection in cystic fibrosis, while achieving high lung concentrations and low systemic exposure in rats. The data will be presented today at the 2015 North American Cystic Fibrosis Conference in Phoenix, Ariz.

PUR1900 is formulated with Pulmatrix's proprietary iSPERSE™ (Inhaled Small Particles Easily Respirable and Emitted) dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects.

Researchers compared the pharmacokinetics and potency of itraconazole against two other antifungal compounds -- amphotericin B and voriconazole -- following intratracheal instillation in rats at doses of up to 1.5 mg/kg. Lung and plasma samples were collected beginning five minutes after instillation for seven to fourteen days. In vitro susceptibility testing was performed using broth microdilution testing against A. fumigatus, as well as A. niger, A. flavus, and 10 to 20 strains of Candida spp.

In rat pharmacokinetic studies, itraconazole showed a long duration of lung retention, with some clearance over a one week period. Subsequent studies with PUR1900 dry powder demonstrated that PUR1900 maintains high concentrations of itraconazole in both lung tissue and in bronchoalevolar lavage samples. Amphotericin B lung concentrations remained constant over one week, while voriconazole was rapidly absorbed and cleared from the lungs.  Most notably, the percentage of administered drug recovered in lung tissue for itraconazole was significantly higher than for amphotericin or voriconazole, and itraconazole had a long lung half-life, which may lead to less frequent dosing in the clinic. All three compounds exhibited potent activity against A.fumigatus in vitro.

"The pharmacokinetics and potency of PUR1900 demonstrate that the drug is likely to achieve the high local concentrations needed to combat fungal infections caused by Aspergillus spp while overcoming oral bioavailability limitations and minimizing systemic side effects such as drug interactions," said David L. Hava, PhD, Pulmatrix's chief scientific officer.

Dr. Richard Moss, emeritus professor of pediatrics at Stanford University, said: "Use of new technologies such as iSPERSE™ to deliver high concentrations of inhaled antifungal drugs directly to the lung have the potential to effectively prevent or treat serious fungal infections or allergies while avoiding problems of toxicities or resistance encountered with systemic use of oral or parenteral antifungals."
Link to Abstract: http://onlinelibrary.wiley.com/doi/10.1002/ppul.23297/full - Poster #393

The 29th Annual North American Cystic Fibrosis Conference is a scientific meeting for medical professionals in the field of cystic fibrosis research and care. The conference is sponsored by The Cystic Fibrosis Foundation.

About Pulmatrix
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis (CF), as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis. In addition, Pulmatrix is pursuing opportunities in major pulmonary diseases through collaborations, including PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD).  Pulmatrix's product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

For more information, visit www.pulmatrix.com. Follow Pulmatrix on Twitter at https://twitter.com/pulmatrix_inc, and on StockTwits at http://stocktwits.com/pulmatrix.Investor ContactMedia ContactTom Baker

David Schull, Russo PartnersDirect: 617-532-0624

Direct: (858) 717-2310tbaker@pulmatrix.com

David.Schull@russopartnersllc.com

 

 


'/>"/>
SOURCE Pulmatrix, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study: Pharmaceutical Government Affairs & Public Policy Groups Role in Supporting the Patient Journey
2. Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data
3. Precision Advisors Digital Trends Study: Pharmas Use of Tablets With Payers Growing in Use But Effectiveness Lags
4. UHC Study: Variations in Use of Physician Preference Items Affect Patient Outcomes and Costs
5. Diovan Case Study: How to Become a Leader in a Crowded Marketplace
6. Study: 2015 Medicare Drug Plans Cover Fewer Drugs & Have More Restrictions
7. ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results
8. Study: 1 out of 5 adult orthopaedic trauma patients sought additional providers for narcotic prescriptions
9. New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015
10. New Study: H.R. 4577 to Cost $21 Billion over 10 Years
11. New Study: Medicare Preferred Pharmacy Network Plans Offer Lower Average Premiums, Same Quality as Non-Preferred Network Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... AccuGenomics, Inc., a diagnostic company based in ... the company has provided an AccuKit to the HIV ... Chapel Hill and to Qura Therapeutics for evaluation in ... HIV reservoir and viral expression in human CD4+ T ... Center is a joint initiative between the University of ...
(Date:8/8/2017)... Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... reports its financial results for the second quarter ended ... the second quarter 2017 and to date: ... development programs for the Company,s lead project, BL-8040: ... study with BL-8040 as novel stem cell mobilization treatment ...
(Date:8/7/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... June 30, 2017.  All comparisons, unless otherwise noted, are to ... Second Quarter 2017 Highlights include: ... an increase of 3.5% Total prescriptions dispensed ... of 7.5% versus 7.6% Gross profit ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... More than 20,000 pairs of ... Congo (DRC) thanks to an ambitious venture that conjoined the passions of an NBA ... support of the Liberty community. These shoes will save lives from the rampant infections ...
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet today announces the launch ... lifestyles and highlighting the importance of proactive eye and ear health. The campaign ... latest innovations in hearing aid technology. , In this issue, the National ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... handling handheld devices. Through an educational webinar, they will present the line of ... chance to learn how easy you can automate everyday pipetting tasks. , Ideal ...
(Date:8/18/2017)... ... 2017 , ... Radabaugh & Associates, a family managed agency ... West Virginia, is embarking on a cooperative charity effort with the Chestnut Mountain ... Chestnut Mountain Ranch (CMR) is a Christ-centered boarding school for young men offering ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Brian Gifford Agency, an ... is campaigning in support of Campagna Academy in a charity drive to provide for ... Boys’ Town of Indiana,” Campagna Academy is a nonprofit organization that has offered critical ...
Breaking Medicine News(10 mins):